October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms

 
• By Bridget Silverman

Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals

pumpkins
• Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers